U.S. Markets open in 1 hr 36 mins

AIkido Pharma Inc. (AIKI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.87+0.02 (+0.34%)
At close: 04:00PM EDT
5.74 -0.13 (-2.21%)
After hours: 06:46PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.85
Bid5.50 x 1100
Ask0.00 x 800
Day's Range5.77 - 5.97
52 Week Range4.30 - 16.66
Avg. Volume82,674
Market Cap526.428M
Beta (5Y Monthly)1.40
PE Ratio (TTM)N/A
EPS (TTM)-0.07
Earnings DateMar 23, 2022 - Mar 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateMay 12, 1980
1y Target Est34.00
  • PR Newswire

    AIkido Pharma, Inc. Hires Carlos Aldavero to Lead Financial Services Subsidiary

    Anthony Hayes, CEO of AIkido Pharma Inc. (NASDAQ: AIKI) ("AIkido" or the "Company"), announced the hiring of Carlos Aldavero as President of Dominari Financial, the recently formed financial services subsidiary of AIkido. Mr. Aldavero joins Dominari from Morgan Stanley where he was Associate Complex Manager overseeing one of the largest and most profitable business units at the venerable Wall St. firm.

  • PR Newswire

    AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements

    AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that on June 23, 2022, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that it has regained compliance with the $1.00 minimum bid price requirement for continued listing on The NASDAQ Capital Market under Listing Rule 5550(a)(2). The Company regained compliance with the NASDAQ's requirements when the closing bid price for the Company's common stock was at o

  • PR Newswire

    AIkido Inc. Announces the Formation of a New Financial Services Subsidiary

    AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") announced the formation of a wholly owned subsidiary with the purpose of making strategic investments and acquisitions across the fintech and financial services industries. The new subsidiary is expected to be the centerpiece of a long-range plan to diversify AIkido's business beyond biotechnology, in order to reduce volatility and mitigate risk while increasing revenue and enhancing shareholder value.